The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study

Inclusion Criteria: 1. Age\>18 years old, gender unlimited; 2. According to the Diagnosis and Treatment Guidelines for Primary Lung Cancer (2018 Edition), NSCLC was diagnosed by pathological histology; 3. TNM staging is III - IV; 4. Failure of second-line treatment according to the CSCO guidelines; 5. ECOG PS score ≤ 2 points; 6. Estimated survival time\>3 months; 7. Sign informed consent form Exclusion Criteria: 1. Individuals who have previously received interventional therapy (iodine particle implantation, ablation, BACE treatment), or have received PD-L1 inhibitor immunotherapy during the first or second line standard treatment period of the patient; 2. Patients with other malignant tumors that have not been cured; 3. White blood cells\<3 × 109/L, absolute value of neutrophils\<1.5 × 109/L, neutrophil/lymphocyte ratio ≥ 3, platelet count\<50 × 109/L, hemoglobin concentration\<90 g/L; 4. Liver and kidney dysfunction (creatinine\>176.8) μ Mol/L; Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)\>twice the normal upper limit; 5. Central squamous cell carcinoma with cavity features; 6. Incorrectable coagulation dysfunction or concomitant active massive hemoptysis; 7. Patients with concurrent active infections who require antibiotic treatment; 8. Uncontrollable hypertension, diabetes, and cardiovascular diseases with obvious symptoms; 9. Contrast agent allergy; 10. Women with concurrent pregnancy or lactation

Reproduced word-for-word from the public registry record — the study team can answer questions about it.